The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Antibiotic prophylaxis in cirrhosis: Good and bad
Open accessAbstract
Patients with cirrhosis, particularly those with decompensated cirrhosis, are at increased risk of bacterial infections that may further precipitate other liver decompensations including acute‐on‐chronic liver failure. Infections constitute the main cause of death in patients with advanced cirrhosis, and strategies to prevent them are essential. The main current strategy is the use of prophylactic antibiotics targeted at specific subpopulations at high risk of infection: prior episode of spontaneous bacterial peritonitis, upper gastrointestinal bleeding, and low‐protein ascites with associated poor liver function. Antibiotic prophylaxis effectively prevents not only the development of bacterial infections in all these indications but also further decompensation (variceal bleeding, hepatorenal syndrome) and improves survival. However, antibiotic prophylaxis is also associated with a clinically relevant and increasing drawback, the development of infections due to multidrug‐resistant organisms. Several strategies have been suggested to balance the risks and benefits of antibiotic prophylaxis. Conclusion: Antibiotic stewardship principles such as the restriction of antibiotic prophylaxis to subpopulations at a very high risk for infection, the avoidance of antibiotic overuse, and early deescalation policies are key to achieve this balance; nonantibiotic prophylactic measures such as probiotics, prokinetics, bile acids, statins, and hematopoietic growth factors could also contribute to ameliorate the development and spread of multidrug‐resistant bacteria in cirrhosis. (H epatology 2016;63:2019‐2031)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Besselink, M. G., van Santvoort, H. C., Buskens, E., Boermeester, M. A., van Goor, H., Timmerman, H. M., Nieuwenhuijs, V. B., Bollen, T. L., van Ramshorst, B., Witteman, B. J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60207-x · Cited by 1,367
Fernández, J., Navasa, M., Gómez, J., Colmenero, J., Vila, J., Arroyo, V., & Rodés, J. (2002) · Hepatology · doi:10.1053/jhep.2002.30082 · Cited by 954
Self-citationBacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013
Jalan, R., Fernandez, J., Wiest, R., Schnabl, B., Moreau, R., Angeli, P., Stadlbauer, V., Gustot, T., Bernardi, M., Canton, R., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.024 · Cited by 906
Fernández, J., Navasa, M., Planas, R., Montoliu, S., Monfort, D., Soriano, G., Vila, C., Pardo, A., Quintero, E., Vargas, V., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.06.065 · Cited by 709
Self-citationBacterial translocation (BT) in cirrhosis†
Wiest, R., & Garcia‐Tsao, G. (2005) · Hepatology · doi:10.1002/hep.20632 · Cited by 677
Bajaj, J. S., Heuman, D. M., Sanyal, A. J., Hylemon, P. B., Sterling, R. K., Stravitz, R. T., Fuchs, M., Ridlon, J. M., Daita, K., Monteith, P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060042 · Cited by 430
Lorenzo-Zúñiga, V., Bartolí, R., Planas, R., Hofmann, A. F., Viñado, B., Hagey, L. R., Hernández, J. M., Mañé, J., Alvarez, M. A., Ausina, V., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50116 · Cited by 321
Verbeke, L., Farre, R., Verbinnen, B., Covens, K., Vanuytsel, T., Verhaegen, J., Komuta, M., Roskams, T., Chatterjee, S., Annaert, P., et al. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2014.10.009 · Cited by 225
Tandon, P., DeLisle, A., Topal, J. E., & Garcia–Tsao, G. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.08.017 · Cited by 158
Self-citationLutz, P., Parcina, M., Bekeredjian-Ding, I., Nischalke, H. D., Nattermann, J., Sauerbruch, T., Hoerauf, A., Strassburg, C. P., & Spengler, U. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093909 · Cited by 55 · cited 1×
“this occurred in 8/27 (30%) patients on rifaximin and 24/108 (22%) not on any prophylaxis.((30)) As systemic absorption of rifaximin increases with worsening liver disease severity, ongoing prospective studies will be important to clarify not only the benefits of rifaximin but also the risk of inducing antibiotic resi…”
Background
Cited by
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
Angeli, P., Bernardi, M., Villanueva, C., Francoz, C., Mookerjee, R. P., Trebicka, J., Krag, A., Laleman, W., & Gines, P. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.024 · Cited by 2,905
Biggins, S. W., Angeli, P., Garcia‐Tsao, G., Ginès, P., Ling, S. C., Nadim, M. K., Wong, F., & Kim, W. R. (2021) · Hepatology · doi:10.1002/hep.31884 · Cited by 846
Self-citationLiver — guardian, modifier and target of sepsis
Strnad, P., Tacke, F., Koch, A., & Trautwein, C. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.168 · Cited by 692
Guidelines on the management of ascites in cirrhosis
Aithal, G. P., Palaniyappan, N., China, L., Härmälä, S., Macken, L., Ryan, J. M., Wilkes, E. A., Moore, K., Leithead, J. A., Hayes, P. C., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-321790 · Cited by 680
Fernández, J., Acevedo, J., Wiest, R., Gustot, T., Amoros, A., Deulofeu, C., Reverter, E., Martínez, J., Saliba, F., Jalan, R., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314240 · Cited by 572
Self-citation
Metadata
- Authors
- Fernández, J., Tandon, P., Mensa, J., & Garcia‐Tsao, G.
- Venue
- Hepatology
- Published
- 2016-01-11
- Volume
- 63
- Issue
- 6
- Pages
- 2019-2031
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W1938866537
- Cited by
- 203
- References
- 10
- FWCI
- 9.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.